NCT04330664: Phase 1/2 Study of MRTX849 Plus TNO155 in Patients With Cancer Having a KRAS G12C Mutation

NCT04330664
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for phase 1; Patients must have a solid tumor malignancy with KRAS G12C mutation
Exclusions: 
https://ClinicalTrials.gov/show/NCT04330664

Comments are closed.

Up ↑